arrow
X

Xiangrui Jiang

Shanghai Institute of Materia Medica
H指数:20
被引数:1,985

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Design, synthesis, and biological evaluation of thioamide-linked spiropyrrolidine derivatives as novel 3CLpro inhibitors against SARS-CoV-2

硫酰胺连接的螺吡咯烷衍生物的设计、合成及其作为新型3CLpro抑制剂对抗SARS-CoV-2的生物学评价

2025-05-140
PRE
Design, Synthesis, and Biological Evaluation of Peptidomimetic Tetrahydropyrrole Spirodihydroindolones as SARS-CoV-2 3CL Protease Inhibitors

拟肽四氢吡咯螺二氢吲哚酮作为SARS-CoV-2 3CL蛋白酶抑制剂的设计,合成和生物学评价

2025-04-010
PRE
A first-in-human phase 1 study of simnotrelvir, a 3CL-like protease inhibitor for treatment of COVID-19, in healthy adult subjects
2023-12-0113
OA
Glimepiride, a novel soluble epoxide hydrolase inhibitor, protects against heart failure via increasing epoxyeicosatrienoic acids

格列美脲是一种新型的可溶性环氧化物水解酶抑制剂,可通过增加环氧二十碳三烯酸来预防心力衰竭

2023-12-012
PRE
Repurposing of Rutan showed effective treatment for COVID-19 disease
2023-11-291
OAAI
Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo- controlled, phase 1b trial

SIM0417 (SSD8432) 联合利托那韦治疗新型冠状病毒肺炎的疗效和安全性: 一项随机、双盲、安慰剂对照的1b期试验

2023-09-0124
OAAI